High-Throughput Synthesis

Motivated by the advancement of genomics and the urgent need of discovery of new molecules with therapeutic interest, as are venom peptides, high throughput pipelines ( have been developed to replace traditional approaches and protocols for synthetic gene synthesis and protein production Several high throughput platforms have been used in the past decade to identify conditions for soluble protein expression or for synthetic DNA production in large scale

Animal venoms are complex molecular cocktails containing a wide range of biologically active disul-

phide-reticulated peptides that target, with high selectivity and efficacy, a variety of membrane receptors. Disulphide- reticulated peptides have evolved to display improved specificity, low immunogenicity and to show much higher resistance to degradation than linear peptides.

This study reveals that E. coli is a convenient heterologous host for the expression of soluble and functional venom peptides. Using the optimal construct design, a large and diverse range of animal venom peptides were produced in the µM scale. These results open up new possibilities for the high-throughput production of recombinant disulphide-rich peptides in E. coli.

At NZYTech we are constantly developing innovative products and services in our main areas of expertise, aiming to achieve the highest standards for laboratory research and industrial analysis. We intend to serve diligently the scientific community and to provide satisfying solutions to customers worldwide. With this in mind we have recently developed a highthroughput (HTP) platform to efficiently generate hundred to thousands of expressing clones, thus leading to the rapid characterization and screening of recombinant proteins that can be applied in subsequent protocols from structure determination to industrial procedures. To achieve this, we have optimized, in a high-throughput away, most of the classical and standard methods used in molecular biology.

At NZYTech we intend to develop, manufacture and market solutions that simplify, accelerate and improve life sciences research. Thus, conscious of the pressures that befall on structural genomics and proteomics as a result of the dramatic increasing number of genome sequences available nowadays, we have recently developed a high-throughput (HTP) platform to efficiently clone and express a large amount of recombinant proteins that can be rapidly used in subsequent protocols for function and structure determination.